A preventive treatment for dementia may proceed to clinical trials after successful animal testing.
The US-led research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the researchers say.
A new paper in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020, with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in South Australia.
The latest research aims to come up with a new treatment to remove accumulated beta-amyloid (A?) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline in Alzheimer’s disease.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, affecting about 5.7 million people in the US. Major challenges in AD include the lack of effective treatments, reliable biomarkers, or preventive strategies.
Professor of the Institute for Molecular Medicine Anahit Ghochikyan and colleagues, Associate Professors Hvat Davtyan and Mathew Blurton-Jones from UCI, and other co-authors tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Professor Petrovsky’s Australian lab.
The possible new therapies were tested in bigenic mice with mix A? and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” the lead authors Professor Ghochikyan and Blurton-Jones conclude.
Professor Petrovsky says the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based A?/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay AD progression in a the rising number of people around the world,” says Professor Petrovsky, who will work in the US for the next three months.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early AD as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a preventive measure in healthy subjects due to the need for frequent (monthly) administration of high concentrations of immunotherapeutic.
Professor Ghochikyan says there is a pressing need to keep searching for new preventive vaccine to delay AD and slow down progression of this devastating disease.
The new combined vaccination approach could potentially be used to induce strong immune responses to both of the hallmark pathologies of AD in a broad population base of vaccinated subjects with high MHC (major histocompatibility complex) class II gene polymorphisms, the new paper concludes.
Go deeper with Bing News on:
- Coronavirus morning recap: WHO says vaccine may be ready by year-end, symptoms and Covid recoveryon October 6, 2020 at 8:06 pm
The WHO says a vaccine may be ready by year-end; researchers want loss of smell to be recognised as a Covid symptom, and tips for recovery from mild cases.
- High demand for flu shots as experts hope to avoid ‘twindemic’on October 1, 2020 at 9:26 pm
October is prime time for flu vaccinations, and the U.S. and Europe are gearing up for what experts hope is high demand as countries seek to avoid a “twindemic” with COVID-19.
- Getting These Vaccines Could Lower Your Alzheimer’s Riskon October 1, 2020 at 5:00 pm
Getting a flu shot is always wise, but especially so this year. It's not the usual blah, blah, blah. Click here to sign up for our free newsletter. The vaccine helps protect against influenza, which ...
- Want to reduce your COVID-19 risk? You need to sleep more.on October 1, 2020 at 3:05 am
Sleep is a simple way to bolster the immune system against colds, influenza, and other respiratory infections.
- Coronavirus Vaccine Study Out Of UCHealth Shows How Antibodies React With Older Adultson September 30, 2020 at 4:33 pm
Early results of a coronavirus vaccine study being conducted in Colorado show that the vaccine candidate in older adults produced virus-neutralizing antibodies at levels similar to those seen in ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- White House approves FDA's vaccine guidelines...on October 7, 2020 at 7:08 am
White House approves FDA's stricter vaccine guidelines", a CBSN video on CBSNews.com. View more CBSN videos and watch CBSN, a live news stream featuring original CBS News reporting.
- White House lifts block on FDA's stricter vaccine requirementson October 7, 2020 at 6:10 am
The agency's decision to hold vaccine developers to the stricter criteria will likely push any vaccine authorization beyond Election Day.
- Covid-19 doctor's diary: I hope we got the winter flu vaccine righton October 7, 2020 at 5:41 am
Inadequate coronavirus testing and uncertainty over the success and supply of flu vaccines will leave doctors in the England poorly prepared to cope this winter ...
- A COVID-19 vaccine by Election Day? Here are the 3 things that would need to happen, and soon.on October 7, 2020 at 4:15 am
Could an approved coronavirus vaccine be released before Election Day on Nov. 3? It's extremely unlikely but not impossible, experts say.
- FDA issues new vaccine guidance that pushes approval past electionon October 7, 2020 at 4:14 am
President Trump said Monday that a vaccine is coming "momentarily," but the FDA says more safety monitoring comes first.